http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 07 Jul 2026 07:38:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html <p>Splash Beverage Group (NYSE American: SBEV) has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT, LSE: RGT) for CannEpil®, a cannabinoid-based therapy used in the treatment of drug-resistant epilepsy, according to a press release dated July 7, 2026.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid treatment approved for distribution in Ireland, the United Kingdom, Germany, and Australia. It is manufactured under European Union Good Manufacturing Practice standards. In Ireland, it is eligible under the Medicinal Cannabis Access Program and is reimbursed through the Health Service Executive. In the UK, it has been authorized for prescription through the Named http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html Tue, 07 Jul 2026 07:38:15 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT SBEV http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html <p>Splash Beverage Group (NYSE American: SBEV) has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT, LSE: RGT) for CannEpil®, a cannabinoid-based therapy used in the treatment of drug-resistant epilepsy, according to a press release dated July 7, 2026.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid treatment approved for distribution in Ireland, the United Kingdom, Germany, and Australia. It is manufactured under European Union Good Manufacturing Practice standards. In Ireland, it is eligible under the Medicinal Cannabis Access Program and is reimbursed through the Health Service Executive. In the UK, it has been authorized for prescription through the Named http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html Tue, 07 Jul 2026 07:38:15 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT SBEV http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html <p>Splash Beverage Group (NYSE American: SBEV) has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT, LSE: RGT) for CannEpil®, a cannabinoid-based therapy used in the treatment of drug-resistant epilepsy, according to a press release dated July 7, 2026.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid treatment approved for distribution in Ireland, the United Kingdom, Germany, and Australia. It is manufactured under European Union Good Manufacturing Practice standards. In Ireland, it is eligible under the Medicinal Cannabis Access Program and is reimbursed through the Health Service Executive. In the UK, it has been authorized for prescription through the Named http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html Tue, 07 Jul 2026 07:38:15 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT SBEV http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html <p>Splash Beverage Group (NYSE American: SBEV) has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT, LSE: RGT) for CannEpil®, a cannabinoid-based therapy used in the treatment of drug-resistant epilepsy, according to a press release dated July 7, 2026.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid treatment approved for distribution in Ireland, the United Kingdom, Germany, and Australia. It is manufactured under European Union Good Manufacturing Practice standards. In Ireland, it is eligible under the Medicinal Cannabis Access Program and is reimbursed through the Health Service Executive. In the UK, it has been authorized for prescription through the Named http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html Tue, 07 Jul 2026 07:38:15 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT SBEV http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html <p>Splash Beverage Group (NYSE American: SBEV) has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT, LSE: RGT) for CannEpil®, a cannabinoid-based therapy used in the treatment of drug-resistant epilepsy, according to a press release dated July 7, 2026.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid treatment approved for distribution in Ireland, the United Kingdom, Germany, and Australia. It is manufactured under European Union Good Manufacturing Practice standards. In Ireland, it is eligible under the Medicinal Cannabis Access Program and is reimbursed through the Health Service Executive. In the UK, it has been authorized for prescription through the Named http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html Tue, 07 Jul 2026 07:38:15 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT SBEV http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html <p>Splash Beverage Group (NYSE American: SBEV) has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT, LSE: RGT) for CannEpil®, a cannabinoid-based therapy used in the treatment of drug-resistant epilepsy, according to a press release dated July 7, 2026.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid treatment approved for distribution in Ireland, the United Kingdom, Germany, and Australia. It is manufactured under European Union Good Manufacturing Practice standards. In Ireland, it is eligible under the Medicinal Cannabis Access Program and is reimbursed through the Health Service Executive. In the UK, it has been authorized for prescription through the Named http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html Tue, 07 Jul 2026 07:38:15 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT SBEV http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html <p>Splash Beverage Group (NYSE American: SBEV) has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT, LSE: RGT) for CannEpil®, a cannabinoid-based therapy used in the treatment of drug-resistant epilepsy, according to a press release dated July 7, 2026.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid treatment approved for distribution in Ireland, the United Kingdom, Germany, and Australia. It is manufactured under European Union Good Manufacturing Practice standards. In Ireland, it is eligible under the Medicinal Cannabis Access Program and is reimbursed through the Health Service Executive. In the UK, it has been authorized for prescription through the Named http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html Tue, 07 Jul 2026 07:38:15 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT SBEV http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html <p>Splash Beverage Group (NYSE American: SBEV) has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT, LSE: RGT) for CannEpil®, a cannabinoid-based therapy used in the treatment of drug-resistant epilepsy, according to a press release dated July 7, 2026.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid treatment approved for distribution in Ireland, the United Kingdom, Germany, and Australia. It is manufactured under European Union Good Manufacturing Practice standards. In Ireland, it is eligible under the Medicinal Cannabis Access Program and is reimbursed through the Health Service Executive. In the UK, it has been authorized for prescription through the Named http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html Tue, 07 Jul 2026 07:38:15 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT SBEV http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html <p>Splash Beverage Group (NYSE American: SBEV) has entered into an exclusive global licensing agreement with Argent BioPharma Limited (ASX: RGT, LSE: RGT) for CannEpil®, a cannabinoid-based therapy used in the treatment of drug-resistant epilepsy, according to a press release dated July 7, 2026.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid treatment approved for distribution in Ireland, the United Kingdom, Germany, and Australia. It is manufactured under European Union Good Manufacturing Practice standards. In Ireland, it is eligible under the Medicinal Cannabis Access Program and is reimbursed through the Health Service Executive. In the UK, it has been authorized for prescription through the Named http://www.streetinsider.com/Mergers+and+Acquisitions/Splash+Beverage+licenses+cannabinoid+epilepsy+therapy+CannEpil+globally/26738491.html Tue, 07 Jul 2026 07:38:15 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT SBEV http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/Press+Releases/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.fl.ftlaud" idsrc="xmltag.org" >FORT LAUDERDALE, Fla.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:SBEV" idsrc="xmltag.org" >Splash Beverage Group, Inc.</span> (NYSE American: SBEV) today announced that it has entered into an exclusive global licensing agreement with <span>Argent BioPharma Limited</span> <span>(ASX: RGT) (LSE: RGT)</span> for CannEpil^®, a proprietary, patent protected cannabinoid-based investigational therapeutic approved for the treatment of drug-resistant epilepsy (DRE) in multiple European countries.</p> <p>CannEpil is a pharmaceutical-grade cannabinoid based treatment that has been approved for distribution in multiple international markets, including <location value="LC/ie" idsrc="xmltag.org" >Ireland</location>, the <location value="LC/gb" idsrc="xmltag.org" >United Kingdom</location>, <location value="LC/de" idsrc="xmltag.org" >Germany</location> and <location value="LC/au" idsrc="xmltag.org" >Australia</location>. The http://www.streetinsider.com/PRNewswire/SPLASH+BEVERAGE+GROUP+ACQUIRES+EXCLUSIVE+GLOBAL+RIGHTS+TO+CANNEPIL%C2%AE%2C+AN+EPILEPSY+THERAPY+WITH+ESTABLISHED+EUROPEAN+PATIENT+ACCESS%2C+FDA+ENGAGEMENT+AND+U.S.+DEVELOPMENT+POTENTIAL/26738485.html Tue, 07 Jul 2026 06:13:00 -0400 A.04229752 A.06822034 MXC O.03969348 O.20026344 O.40361998 O.50922535 RGT RGT SBEV